...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

National Cancer Institute Definitions:

castrate-resistant prostate cancer (ZEN-3694)

Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
 

hormone-sensitive prostate cancer (Failed Trial)

Prostate cancer that needs androgens (male hormones) to grow and therefore stops growing when androgens are not present. Many early-stage prostate cancers are androgen-dependent, so reducing the amount of androgens in the body or blocking their action may be an effective type of therapy. Also called androgen-dependent prostate cancer, androgen-sensitive prostate cancer, castrate-sensitive prostate cancer, CSPC, and HSPC.
 
 
Koo

 

Share
New Message
Please login to post a reply